Imaging Biometrics (IB), a provider of advanced visualization and analytical software solutions, has entered an agreement with the American College of Radiology Imaging Network (ACRIN) to evaluate MRI datasets using its proprietary dynamic susceptibility contrast (DSC) MR perfusion software, IB Neuro.
The ACRIN trial 6677 is a global multi-center phase II trial using imaging to track the effectiveness of biological treatments for brain tumors.
The company said its IB Neuro uses DSC algorithms to provide information about blood volume and blood flow in the brain. The critical perfusion parameters are valuable for detecting new tumor growth or tumor recurrence, and should assist in tailoring personalized treatment plans for patients, IB said.
“This study marries advanced imaging techniques with one of the most important topics in oncology today: antiangiogenic drugs. We hope that by doing this study we’ll understand better how antiangiogenic drugs work, how imaging can shed light on making decisions about therapeutic choices, and how to better develop improved treatments for cancer,” said ACRIN principal investigator Gregory Sorensen, MD, Harvard professor and co-director of the A.A. Martinos Center for biomedical imaging at Massachusetts General Hospital in Boston.
The Milwaukee-based IB said its IB Neuro incorporates proprietary algorithms to correct for contrast agent leakage to more consistently distinguish between normal and abnormal tissue.